The dual mechanism provides complementary glucose-lowering effects through amylin-mediated glucagon suppression and GLP-1-mediated insulin secretion
The punchline is not "Ozempic is bad." The punchline is "Ozempic is crude." Ten years from now, the idea that we handed everyone the same weekly injection regardless of their biomarkers, genetics, training status, age, and goals is going to look quaint
Shipping depends on the patients location, pharmacy availability and applicable regulations
"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial." The New England Journal of Medicine, 2023
Because retatrutide is investigational, its complete adverse-event profile is not yet defined by approved prescribing information
Weeks 5 through 8: 2 mg weekly